Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025 - Top-Institutions - MDSpire

Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025

  • By

  • Darren M. C. Poon

  • Philip W. K. Kwong

  • Samson Y. S. Chan

  • Brian S. H. Ho

  • Martin H. C. Lam

  • K. S. Law

  • Angus K. C. Leung

  • Clarence L. H. Leung

  • David K. W. Leung

  • W. K. Ma

  • Barry B. W. Wo

  • Kenneth C. W. Wong

  • Philip Y. Wu

  • Peter K. F. Chiu

  • April 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Surgical Oncology

  • #2

    Dana-Farber Cancer Institute / Brigham and Women’s Hospital
    Dana-Farber Cancer Institute / Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Translational Research

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Radiation Oncology

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urologic Oncology
    • Surgical Oncology
    • Medical Oncology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Clinical Research

Original Source(s)

Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025

  • by Darren M. C. Poon, Philip W. K. Kwong, Samson Y. S. Chan, Brian S. H. Ho, Martin H. C. Lam, K. S. Law, Angus K. C. Leung, Clarence L. H. Leung, David K. W. Leung, W. K. Ma, Barry B. W. Wo, Kenneth C. W. Wong, Philip Y. Wu, Peter K. F. Chiu

  • April 23, 2026

Related Content

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Biotech exec Jeremy Levin on the industry’s strategic turning point

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study